

Aurobindo Pharma

Estimate change	
TP change	
Rating change	

Motilal Oswal values your support in the Asiamoney Brokers Poll 2021 for India Research, Sales, Corporate Access and Trading team. We [request your ballot](#).



Bloomberg	ARBP IN
Equity Shares (m)	586
M.Cap.(INRb)/(USDb)	446 / 6
52-Week Range (INR)	1064 / 738
1, 6, 12 Rel. Per (%)	-25/-26/-58
12M Avg Val (INR M)	2926

Financials & Valuations (INR b)

Y/E MARCH	2021	2022E	2023E
Sales	247.7	247.0	268.8
EBITDA	53.9	55.1	61.3
Adj. PAT	31.7	33.0	36.8
EBIT Margin (%)	17.5	17.4	17.9
Cons. Adj. EPS (INR)	54.0	56.3	62.8
EPS Gr. (%)	9.9	4.2	11.6
BV/Sh. (INR)	374.3	427.4	486.3
Ratios			
Net D:E	0.0	-0.1	-0.2
RoE (%)	16.3	14.0	13.8
RoCE (%)	13.6	12.0	12.2
Payout (%)	2.7	6.2	6.4
Valuations			
P/E (x)	14.1	13.5	12.1
EV/EBITDA (x)	8.2	7.8	6.5
Div. Yield (%)	0.3	0.5	0.5
FCF Yield (%)	1.6	2.4	6.8
EV/Sales (x)	1.8	1.7	1.5

Shareholding pattern (%)

As On	Jun-21	Mar-21	Jun-20
Promoter	51.8	51.9	52.0
DII	14.7	13.2	12.6
FII	23.7	24.4	22.6
Others	9.8	10.5	12.8

FII Includes depository receipts

CMP: INR760

TP: INR900 (+18%)

Buy

Pricing pressure drags profitability

Product approvals key to benefit from the acquisition

- ARBP delivered a miss on 1QFY22 earnings, led by increases in pricing pressure in the US Generics segment and reduced offtake of ARV medicines. It has recently allocated ~USD160m for forward integrating/enhancing product offerings in the Veterinary space and adding ANDAs in the US Generics segment.
- We reduce our FY22E/FY23E EPS estimate by 5%/6% to factor in higher competition in US Generics and lower other income to account for the usage of capital for acquisitions. We value ARBP at 14x its 12-month forward earnings to arrive at our TP of INR900. ARBP is working on building a complex product pipeline. However, timely approval remains critical for a better growth outlook over the next 2-3 years. We maintain our Buy rating.

Lower US/ARV sales led to a YoY earnings decline

- Sales declined by 4% YoY to INR57b in 1QFY22 (est. INR62.2b). The decline was largely led by lower Formulation sales (down 5% YoY to INR49b) and divestment of the Natrol business.
- US Formulation sales declined by 1.5% YoY to INR26.8b (USD364m; 47% of sales). ARV sales fell 30% YoY to INR3b in 1QFY22 (5% of sales).
- EU Formulation sales grew 19.7% YoY to INR15.8b (28% of sales). Sales in growth markets grew 13.7% YoY to INR3.3b (6% of sales). API sales grew 4.1% YoY to INR8.12b (14% of sales)
- Gross margin contracted by 90bp YoY to 58.5% due to the product mix.
- EBITDA margin contracted by 100bp to 21.2% (est. 21.3%) due to lower gross margin. Lower other expense (-200bp as a percentage of sales) was offset by increase in R&D expenses (+200bp as a percentage of sales).
- EBITDA fell 8% YoY to INR12.1b (est. INR13.2b).
- Adjusting for the forex gain of INR286m, PAT declined by 7% YoY to INR7.5b (est. INR8.2b) due to lower EBITDA margin, partially offset by a lower tax rate in 1QFY22.

Highlights from the management commentary

- ARBP acquired nine marketed OTC brands and six ANDAs for USD104m. It expects a potential annual revenue of USD30m from these six ANDAs.
- It has entered into an agreement to acquire 51% stake in Cronus Pharma for INR4.2b, through primary infusion. These funds would be utilized to repay debt (INR1.7b) and as filing fees/to conduct exhibit batches. The capital employed in Cronus till date stands ~USD50m
- It has received Form 483, with seven procedural observations, post the recently concluded USFDA inspection at Unit 1.
- There was a high single-digit price erosion in the US in 1QFY22, which was higher than usual. Price erosion is mainly due to higher inventories in the channel and subsequent dumping.

Valuation and view

- We lower our FY22E/FY23E EPS estimate by 5%/6% to factor in intense competition in US Generics, lower other income, and lesser ARV sales.
- We expect 8% earnings CAGR over FY21-23E, led by launches in key markets (US/EU) and from the acquired Veterinary business, better profitability in Europe, lower financial leverage, and controlled costs.
- We value ARBP at 14x its 12-month forward earnings to arrive at our TP of INR900. ARBP's efforts are underway a) to enhance product offerings comprising Oncology, Hormones, Depot Injections, Inhalers, Biosimilars, Topicals, and Patches, and b) improving margin in the EU business. We maintain our Buy rating.

Consolidated quarterly performance

(INR b)

Y/E March	FY21				FY22				FY21	FY22E	FY22E
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE		1QE	Var.
Net Sales	59.2	64.8	63.6	60.0	57.0	59.2	63.2	67.5	247.7	247.0	62.2 -8.3%
YoY Change (%)	8.8	15.8	8.0	-2.5	-3.8	-8.6	-0.6	12.5	7.3	-0.3	4.9
EBITDA	13.2	14.3	13.7	12.7	12.1	13.0	14.4	15.6	53.9	55.1	13.2 -8.7%
YoY Change (%)	14.9	22.7	13.3	-5.0	-8.2	-9.1	4.9	22.4	10.9	2.1	0.5
Margin (%)	22.2	22.1	21.5	21.2	21.2	22.0	22.7	23.1	21.8	22.3	21.3
Depreciation	2.6	2.6	2.8	2.7	2.8	2.8	3.0	3.6	10.6	12.2	2.7
EBIT	10.6	11.8	10.9	10.1	9.3	10.2	11.4	12.0	43.4	42.9	10.5
YoY Change (%)	17.3	27.2	14.0	-9.1	-12.4	-13.0	4.0	19.5	11.3	-1.0	-0.7
Interest	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.7	0.5	0.2
Other Income	0.9	0.5	0.3	0.6	0.8	0.8	0.8	0.6	2.4	3.0	0.6
PBT before EO expense	11.3	12.1	11.1	10.5	10.0	10.9	12.0	12.6	45.0	45.4	11.0 -8.9%
Forex loss/(gain)	0.4	-0.1	-0.6	-0.1	-0.3	0.0	0.0	0.0	-0.4	-0.3	0.0
Exceptional (expenses)/income	0.0	0.0	28.5	0.0	0.0	0.0	0.0	0.0	28.5	0.0	0.0
PBT	11.0	12.1	40.2	10.7	10.3	10.9	12.0	12.6	74.0	45.7	11.0 -6.3%
Tax	3.0	3.9	10.6	2.6	2.5	2.8	3.2	3.6	20.1	12.1	2.8
Rate (%)	27.7	31.9	26.3	24.3	24.1	25.5	27.0	28.8	27.2	26.5	25.5
Minority Interest	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.6	0.4	0.0
Reported PAT	7.8	8.1	29.5	8.0	7.7	8.0	8.6	8.8	53.3	33.2	8.2 -5.9%
Adj. PAT	8.1	8.0	7.7	7.9	7.5	8.0	8.6	8.8	31.7	33.0	8.2 -8.5%
YoY Change (%)	26.0	19.7	8.1	-8.2	-7.4	0.1	12.8	11.8	9.9	4.2	1.2
Margin (%)	13.6	12.4	12.0	13.2	13.1	13.5	13.7	13.1	12.8	13.4	13.2

Key performance indicators (consolidated, INR b)

Y/E March	FY21				FY22				FY21	FY22E	FY21E
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			
Formulations	51.4	56.5	56.8	52.0	48.9	51.0	54.9	59.2	216.9	214.0	54.1
YoY Change (%)	9.2	17.9	11.3	-3.6	-4.9	-9.8	-3.4	13.8	8.4	-1.3	5.2
ARV Form.	4.3	5.0	4.4	4.9	3.0	3.3	4.7	6.7	18.6	17.7	5.0
YoY Change (%)	33.6	111.4	41.5	28.6	-30.3	-35.0	7.0	36.9	48.8	-5.0	18.0
US Generic Form.	31.1	31.9	31.7	28.6	26.8	27.8	29.5	30.7	123.2	114.8	30.1
YoY Change (%)	15.6	12.5	6.8	-4.5	-13.7	-13.0	-7.0	7.5	7.3	-6.9	-3.0
EU and RoW Form.	16.1	19.6	20.7	18.6	19.1	20.0	20.7	21.8	75.0	81.6	19.0
YoY Change (%)	-5.5	14.0	13.5	-8.4	18.6	2.0	0.0	17.4	3.0	8.8	17.7
APIs	7.8	8.3	6.8	7.9	8.1	8.2	8.3	8.3	30.9	33.0	8.0
YoY Change (%)	6.6	2.9	-13.6	5.1	4.1	-1.0	22.0	4.6	0.1	6.8	3.0
Cost Break-up											
RM Cost (as a percentage of sales)	40.6	38.8	40.4	40.1	41.5	41.2	40.8	40.6	40.0	41.0	40.2
Staff Cost (as a percentage of sales)	15.0	14.1	13.8	14.2	15.3	14.8	14.0	13.3	14.3	14.3	14.3
R&D Expenses (as a percentage of sales)	4.3	6.3	6.1	7.6	6.3	6.2	6.2	6.1	6.1	6.2	7.4
Other Cost (as a percentage of sales)	17.8	18.7	18.4	16.8	15.8	15.8	16.3	16.8	17.9	16.2	16.8
Gross Margin (%)	59.4	61.2	59.6	59.9	58.5	58.8	59.2	59.4	60.0	59.0	59.8
EBITDA Margin (%)	22.2	22.1	21.5	21.2	21.2	22.0	22.7	23.1	21.8	22.3	21.3
EBIT Margin (%)	17.9	18.1	17.2	16.8	16.3	17.3	18.0	17.8	17.5	17.4	17.0




Highlights from the management commentary

- From the capital employed of USD50m till date in Cronus, ~USD32m has been spent on building a facility.
- In case of the Veterinary segment, a fee is paid to the USFDA at the time of the product's approval, unlike in Generic products, where the fees are to be paid at the time of filing.
- Cronus' pro forma financials indicate USD13m of sales in FY21. It has the potential to touch up to USD100m over the next three years, subject to product approvals.
- Cronus' pipeline of 67 products consists of 40 Injectables. The company has filed 22 products till date. Of the 67 products, 61 are organically developed, while six have been outsourced for manufacturing.
- USFDA's approval for the Cronus facility has been delayed due to the COVID-19 outbreak. It now expects an inspection by CY21-end or early CY22.
- ARBP is expecting 30 product launches in the US in FY22.
- It will file the first two Biosimilars in Europe in FY22. The expected approval timeline is seven months after the filing. One additional product is to be filed in FY23. It will add 1-2 products every year after that.
- ARBP has started Phase III clinical trials for a COVID-19 vaccine.
- The company has sought clarity from the government on some of the concerns in the PLI scheme before starting the financial outlay.


Key exhibits

Exhibit 1: Revenue declines by 4% YoY in 1QFY22




Source: MOFSL, Company

Exhibit 2: US sales declines by ~14% YoY and 1.5% excluding Natrol




Source: MOFSL, Company

Exhibit 3: EU sales grew by ~20% YoY in 1QFY22




Source: MOFSL, Company

Exhibit 4: API sales grew by ~4% YoY




Source: MOFSL, Company

Exhibit 5: ARBP filed eight ANDAs in 1QFY22



Source: MOFSL, Company

Exhibit 6: Gross margin contracts by 90bp YoY



Source: MOFSL, Company

Complex products in focus for US/Europe

Building a complex pipeline in the US for a better outlook over the next 4-5 years

- In constant currency terms, ARBP exhibited 1% YoY growth in US revenue in 1QFY22, adjusted for the Natrol business. Performance was impacted by increased channel inventory, leading to higher than normal pricing pressures.
- ARBP has a strong pipeline, with 174 ANDAs pending approval, of which 52 are Injectables.
- Over the next 2-3 years, it is focusing on a differentiated product portfolio in the US and other geographies. It is developing various products in Oncology, Hormones, Depot Injections, Inhalers, Biosimilars, Topicals, and Patches, which will aid growth in the US business, with margin expansion opportunities. Its existing business, largely comprising of OSDs, benefits from new business opportunities as well as one-time buys, with its large diversified product portfolio. Being a backward integrated manufacturer, ARBP is well placed to sustain superior profitability.
- Considering: a) complex products in the development phase, b) awaiting further clarity on incremental business from the recently acquired ANDA/Veterinary products, and c) deletion of the Natrol business, we expect US sales to be flat over FY21-23E at USD1.6b over FY21-23E.

EU strategy evolving as planned

- Sales in the EU grew by ~20% YoY to INR16b in 1QFY22. Around 50% of products sold in Europe are now sourced from India. ARBP is on track to: a) continue the shift in manufacturing to India, b) enter newer geographies such as Eastern Europe, and c) expand its product offerings, including Injectables and Eugia's Oncology product portfolio. To this end, it has launched 23 products in FY21.
- The portfolio will further be augmented with Biosimilars, the first of which is expected to be launched in 2HCY22. The management has guided at two fillings in FY22 and 1-2 fillings annually in Europe.
- We expect 10% sales CAGR in Europe to INR73b over FY21-23E.


Acquisitions to support growth

- ARBP has acquired a portfolio of nine marketed OTC brands and six ANDAs for USD104m. The six ANDAs are expected to clock an annual revenue of USD30m after approval.
- It acquired 51% stake in Cronus Pharma, which forward integrates as well as enhances ARBP's product offerings in the Veterinary space. Cronus has 22 filings that are pending approval and a total pipeline of 67 products, with six already approved. Cronus' filing approval process is delayed by over a year due to the inability of the USFDA to travel for inspection. Over the next 2-3 years, the management expects to scale up the Cronus business to USD100m per year, contingent on product approvals.

Pricing pressure to be near term headwinds


- We reduce our FY22E/FY23E EPS estimate by 5%/6% to factor in higher competition in US Generics and lower other income on account for the usage of capital for acquisitions.
- We value ARBP at 14x its 12-month forward earnings to arrive at our TP of INR900. The robust product pipeline comprising Complex Generics (Oncology, Hormones, Depot Injections, Inhalers, Biosimilars, Topicals, and Patches), Vaccines, and its presence across the manufacturing value chain keeps ARBP in good stead for a better outlook over the next 2-3 years. We maintain our Buy rating.

Exhibit 7: P/E chart



Source: MOFSL, Company, Bloomberg


Exhibit 8: P/B chart



Source: MOFSL, Company, Bloomberg


Story in charts

Exhibit 9: Expect 4% sales CAGR over FY21-23E




Source: Company, MOFSL

Exhibit 10: Expect US sales to remain flat over FY21-23E




Source: Company, MOFSL

Exhibit 11: Expect EBITDA margin to grow over FY21-23E




Source: Company, MOFSL

Exhibit 12: Expect ~7% EBITDA CAGR over FY21-23E




Source: Company, MOFSL

Exhibit 13: R&D expense to be steady on an absolute basis



Source: Company, MOFSL

Exhibit 14: Expect ~8% EPS CAGR over FY21-23E



Source: Company, MOFSL

Financials and valuations

Consolidated Income Statement									(INR b)
Y/E March	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E
Total Income from Operations	121.2	139.6	150.9	165.0	195.6	231.0	247.7	247.0	268.8
Change (%)	49.6	15.1	8.1	9.3	18.6	18.1	7.3	-0.3	8.8
Total Expenditure	95.6	107.7	116.6	127.1	155.4	182.3	193.8	191.9	207.5
EBITDA	25.6	31.9	34.3	37.9	40.2	48.6	53.9	55.1	61.3
Margin (%)	21.2	22.8	22.8	23.0	20.6	21.1	21.8	22.3	22.8
Depreciation	3.3	3.9	4.3	5.6	6.7	9.7	10.6	12.2	13.2
EBIT	22.3	28.0	30.1	32.3	33.5	39.0	43.4	42.9	48.1
Int. and Finance Charges	0.8	0.9	0.7	0.8	1.6	1.6	0.7	0.5	0.6
Other Income	0.8	0.7	0.5	1.0	1.2	0.9	2.4	3.0	2.5
PBT bef. EO Exp.	22.3	27.7	29.9	32.5	33.1	38.2	45.0	45.4	50.0
EO Items	-0.6	-0.3	0.6	-0.2	-2.2	-0.7	29.0	0.3	0.0
PBT after EO Exp.	21.7	27.4	30.6	32.4	30.9	37.6	74.0	45.7	50.0
Current Tax	6.0	7.2	7.6	8.2	7.3	9.1	20.1	12.1	13.2
Tax Rate (%)	27.5	26.3	24.9	25.3	23.5	24.3	27.2	26.5	26.5
Less: Minority Interest	0.0	0.0	-0.1	0.0	0.0	0.1	0.6	0.4	-0.1
Reported PAT	15.8	20.3	23.0	24.2	23.6	28.3	53.3	33.2	36.8
Adjusted PAT	15.8	20.3	23.0	25.0	25.3	28.8	31.7	33.0	36.8
Change (%)	19.1	28.5	13.6	8.7	1.1	13.9	9.9	4.2	11.6
Margin (%)	13.0	14.5	15.3	15.2	12.9	12.5	12.8	13.4	13.7

Consolidated Balance Sheet									(INR b)
Y/E March	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E
Equity Share Capital	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
Total Reserves	51.0	72.3	93.1	116.2	138.3	167.5	218.7	249.8	284.3
Net Worth	51.6	72.9	93.7	116.8	138.9	168.1	219.3	250.4	284.9
Minority Interest	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Liabilities	2.1	-1.8	-1.2	0.8	1.0	1.4	1.2	1.2	1.3
Total Loans	38.6	44.2	30.8	44.8	67.5	54.2	49.7	42.1	33.6
Capital Employed	92.5	115.2	123.4	162.4	207.4	223.7	270.2	293.8	319.8
Gross Block	53.8	41.3	53.6	70.7	98.0	116.4	134.3	155.0	167.5
Less: Accum. Deprn.	17.4	3.5	7.2	11.8	18.3	28.0	38.5	50.7	63.9
Net Fixed Assets	36.4	37.9	46.5	58.9	79.7	88.4	95.8	104.4	103.6
Goodwill on Consolidation	0.6	4.1	4.1	8.2	8.3	9.2	4.3	4.3	4.3
Capital WIP	4.2	8.4	12.4	14.0	13.4	16.2	24.3	24.3	24.3
Total Investments	0.2	1.2	2.5	3.1	3.6	5.5	5.9	5.9	5.9
Curr. Assets, Loans and Adv.	87.6	105.6	95.4	125.3	157.7	168.3	203.8	211.9	243.1
Inventory	36.1	40.6	43.3	58.6	72.5	77.0	90.3	88.8	89.7
Account Receivables	35.4	46.1	35.0	38.7	34.1	43.2	35.0	40.6	49.3
Cash and Bank Balance	4.7	7.9	5.1	12.6	19.6	28.4	54.7	58.0	79.6
Loans and Advances	11.5	11.1	12.0	15.4	31.5	19.7	23.7	24.5	24.5
Curr. Liability and Prov.	36.6	41.9	37.4	47.1	55.3	63.9	63.8	57.0	61.5
Account Payables	20.5	24.6	24.9	26.3	25.5	25.4	27.9	26.4	30.9
Other Current Liabilities	13.6	15.8	11.4	18.2	26.1	33.5	32.6	30.0	30.0
Provisions	2.4	1.6	1.1	2.6	3.6	4.9	3.3	0.6	0.6
Net Current Assets	51.1	63.7	58.0	78.3	102.4	104.3	140.0	154.9	181.7
Deferred Tax assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Appl. of Funds	92.5	115.2	123.4	162.4	207.4	223.7	270.2	293.8	319.8

Financials and valuations

Ratios

Y/E March	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E
Basic (INR)									
EPS	27.0	34.6	39.3	42.7	43.2	49.2	54.0	56.3	62.8
Cash EPS	32.7	41.3	46.6	52.2	54.6	65.7	72.0	77.0	85.4
BV/Share	88.3	124.5	160.0	199.4	237.1	286.9	374.3	427.4	486.3
DPS	2.2	2.3	1.9	3.7	2.5	2.5	2.5	3.5	4.0
Payout (%)	9.9	8.0	6.0	10.9	6.8	5.2	2.7	6.2	6.4
Valuation (x)									
P/E	28.2	22.0	19.3	17.8	17.6	15.5	14.1	13.5	12.1
Cash P/E	23.3	18.4	16.3	14.6	13.9	11.6	10.6	9.9	8.9
P/BV	8.6	6.1	4.8	3.8	3.2	2.6	2.0	1.8	1.6
EV/Sales	4.0	3.5	3.1	2.9	2.5	2.0	1.8	1.7	1.5
EV/EBITDA	18.7	15.1	13.7	12.6	12.3	9.7	8.2	7.8	6.5
Dividend Yield (%)	0.3	0.3	0.3	0.5	0.3	0.3	0.3	0.5	0.5
FCF per share	-3.5	5.3	27.0	7.2	1.6	50.4	12.5	18.5	51.9
Return Ratios (%)									
RoE	35.4	32.5	27.6	23.8	19.8	18.8	16.3	14.0	13.8
RoCE	20.4	20.4	19.0	17.4	14.4	14.1	13.6	12.0	12.2
RoIC	20.9	22.8	22.5	20.4	16.9	17.1	17.6	16.1	17.0
Working Capital Ratios									
Fixed Asset Turnover (x)	2.3	3.4	2.8	2.3	2.0	2.0	1.8	1.6	1.6
Inventory (Days)	198	227	238	275	277	280	308	323	298
Debtor (Days)	91	107	98	82	68	61	58	56	61
Creditor (Days)	113	134	140	138	109	96	98	98	96
Working Cap. (Days)	177	200	196	219	235	246	267	281	264
Leverage Ratio (x)									
Current Ratio	2.4	2.5	2.6	2.7	2.9	2.6	3.2	3.7	4.0
Interest Coverage Ratio	26	30	45	42	21	24	58	89	79
Net Debt/Equity	0.7	0.5	0.3	0.3	0.3	0.2	0.0	-0.1	-0.2

Consolidated Cash Flow Statement

(INR b)

Y/E March	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E
OP/(Loss) before Tax	22.3	27.4	30.6	32.4	30.9	37.4	45.0	45.4	50.0
Depreciation	3.3	3.9	4.3	5.6	6.7	9.7	10.6	12.2	13.2
Interest/Dividend received	0.8	0.7	0.4	0.5	1.4	1.2	-1.6	-2.5	-1.9
Direct Taxes Paid	-6.0	-7.3	-7.7	-7.0	-7.7	-7.3	-20.1	-12.1	-13.2
(Inc.)/Dec. in WC	-2.5	-10.8	5.3	-10.4	-14.8	2.8	-9.3	-11.7	-5.2
CF from Operations	18.0	13.9	32.9	21.2	16.4	43.8	24.5	31.3	42.9
Others	-5.6	3.7	-0.1	-1.6	0.1	0.0	8.7	0.3	0.0
CF from Operations incl. EO	12.4	17.6	32.8	19.5	16.5	43.8	33.3	31.6	42.9
(inc.)/dec. in FA	-14.4	-14.5	-16.9	-15.3	-15.6	-14.3	-26.0	-20.7	-12.5
Free Cash Flow	-2.0	3.1	15.8	4.2	0.9	29.5	7.3	10.9	30.4
(Pur.)/Sale of Investments	-0.3	0.0	-0.9	-4.0	-13.4	-1.4	0.4	0.0	0.0
CF from Investments	-14.1	-13.8	-17.9	-19.3	-29.0	-15.7	6.0	-20.7	-12.5
Inc./(Dec.) in Debt	2.3	6.0	-17.3	2.9	26.2	-13.1	-4.5	-7.6	-8.5
Interest Paid	-0.8	-0.8	-0.6	-0.7	-1.5	-1.3	-0.7	-0.5	-0.6
Dividend Paid	-1.6	-1.6	-1.4	-2.6	-1.6	-1.9	-1.5	-2.1	-2.3
Others	1.1	-3.4	1.5	7.7	-3.4	-2.8	-6.9	2.6	2.6
CF from Fin. Activity	1.0	0.2	-17.7	7.2	19.8	-19.1	-13.6	-7.6	-8.8
Inc./Dec. in Cash	-0.7	4.0	-2.8	7.5	7.3	9.1	25.6	3.3	21.6
Opening Balance	1.5	4.7	7.9	5.1	12.6	19.6	28.4	54.7	58.0
Others incl. impact of FX	3.9	-0.8	0.0	0.0	-0.3	-0.2	0.7	0.0	0.0
Closing Balance	4.7	7.9	5.1	12.6	19.6	28.4	54.7	58.0	79.6

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations). Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOFSL is a subsidiary company of Passionate Investment Management Pvt. Ltd.. (PIMPL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents>List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL , including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company
- received compensation/other benefits from the subject company in the past 12 months

- other potential conflict of interests with respect to any recommendation and other related information and opinions., however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Patel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 71934200/ 022-71934263; Website www.motilaloswal.com; CIN no.: L67190MH2005PLC153397. Correspondence Office Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad(West), Mumbai-400 064. Tel No: 022 7188 1000.

Registration Nos.: Motilal Oswal Financial Services Limited (MOFSL)*: INZ000158836(BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN - 146822; Investment Adviser: INA000007100; Insurance Corporate Agent: CA0579; PMS: INP000006712. Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP00000670); PMS and Mutual Funds are offered through MOAMC which is group company of MOFSL. Motilal Oswal Wealth Management Ltd. (MOWML): PMS (Registration No.: INP000004409) is offered through MOWML, which is a group company of MOFSL. Motilal Oswal Financial Services Limited is a distributor of Mutual Funds, PMS, Fixed Deposit, Bond, NCDs, Insurance Products and IPOs. Real Estate is offered through Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. which is a group company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Ltd which is a group company of MOFSL. Research & Advisory services is backed by proper research. Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market is subject to market risk, read all the related documents carefully before investing. Details of Compliance Officer: Name: Neeraj Agarwal, Email ID: na@motilaloswal.com, Contact No.: 022-71881085.

* MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench.